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1. Introduction 
Colorectal cancer is the third most common cancer in women and fourth in men, with 
respect to incidence, and 529,000 deaths occurred worldwide in 2002 (Parkin et al., 2005). 
Approximately 2 ‐ 5% of cases of colorectal cancer are due to a genetic predisposition of 
which the most common is hereditary non‐polyposis colorectal cancer (HNPCC). HNPCC is 
an autosomal dominant disorder with high penetrance and exhibits allelic and locus 
heterogeneity (Aarnio et al., 1995; de la Chapelle, 2004; Dunlop et al., 1997). In HNPCC there 
are heterozygous germline mutations in the DNA mismatch repair (MMR) genes MutS 
homologue 2 (MSH2), MutL homologue 1 (MLH1), MutS homologue 6 (MSH6), post‐meiotic 
segregation increased 2 (PMS2) and post‐meiotic segregation increased 1 (PMS1) (Bocker et 
al., 1999; Buermeyer et al., 1999; Jiricny, 1998; Jiricny & Marra, 2003; Lucci-Cordisco et al., 
2003; Mitchell et al., 2002; Narayan & Roy, 2003; Nicolaides et al., 1998; Plaschke et al., 2004; 
Zabkiewicz & Clarke, 2004). Germline mutations in hMLH1 and hMSH2 are the most 
common with abnormalities in these genes found in more than 90% of HNPCC mutation 
carriers (Abdel-Rahman et al., 2006; de la Chapelle, 2004; Hampel et al., 2005; Lagerstedt 
Robinson et al., 2007). The phenomenon of transmission of an epimutation in hMLH1 has 
also been reported (Hitchins et al., 2007).  
The DNA MMR system plays an essential role in identifying and correcting any replication 
errors and any additional errors which arise through physical or chemical damage. These 
errors may be base‐base mismatches, short insertions/deletions and heteroduplexes, which 
can occur during DNA replication and recombination (Jiricny, 1998; Jiricny & Marra, 2003). 
The DNA MMR system therefore maintains genomic integrity and stability and in essence 
provides a tumour suppressor function. Deficiencies in DNA MMR lead to the accumulation 
of mutations in repetitive nucleotide regions, a phenomenon termed microsatellite 
instability (MSI) (Parsons et al., 1993; Parsons et al., 1995; Thibodeau et al., 1993; Thibodeau et 
al., 1998). Microsatellites are classically defined as simple tandem nucleotide sequence 
repeats of 1 – 6 base pairs in the genome (Hancock, 1999). Changes in the number of the 
repeat units due to defective DNA MMR are potentially cancer causing (Riccio et al., 1999; 
Yamamoto et al., 1998). The MSI phenotype or replication error positive (RER+) phenotype 
can be considered as an almost canonical feature of DNA MMR deficiency (Kinzler & 
Vogelstein, 1996; Parsons et al., 1993). This MSI phenotype is observed in approximately 15% 
of all human colorectal cancer, gastric and endometrial carcinomas (Lothe et al., 1993; Seruca 
et al., 1995; Shibata, 1999; Umar et al., 1994). Somatic inactivation of DNA MMR largely 
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arises as a consequence of epigenetic silencing of hMLH1 (through hypermethylation of 
promoter CpG islands) rather than via classic mutational inactivation (Herman et al., 1998; 
Jacinto & Esteller, 2007; Jones & Laird, 1999; Peltomaki, 2001; H. Yamamoto et al., 1998). 
Genes particularly prone to MSI include Bax, TGF-β receptor II, hMSH3 and hMSH6 
(Yamamoto et al., 1998); other susceptible genes include the DNA glycosylase MBD4 (Bader 
et al., 2000; Bader et al., 1999; Riccio et al., 1999) and the epidermal growth factor receptor 
(EGFR) (Woerner et al., 2010). Additionally, as a consequence of MSI, inactivation of proteins 
in the Wnt signalling pathway (eg TCF-4) has been reported (Shimizu et al., 2002). Clinically 
defined MSI is where at least two of the loci tested in a panel out of five exhibit instability 
(Boland et al., 1998). Mutation frequencies in cells defective in DNA MMR can be increased 
100-1000 fold (Parsons et al., 1993; Shibata, 1999).  
The protective role of the DNA MMR system in suppressing the mutator phenotype in a 
range of common cancers is thus well established. The hypothesis that aspirin may 
potentially modulate this pathway to prevent carcinogenesis (Goel et al., 2003) is of central 
interest, and has so far received relatively little attention and merits further investigation. 
The aim of this chapter will be to review the evidence that non-steroidal anti-inflammatory 
drugs (NSAIDS), including aspirin, celecoxib, sulindac and so on, affect DNA repair 
mechanisms and pathways and to further examine the consequences of this in relation to 
cancer development and progression. As NSAIDs are considered to be one of the most 
widely used over-the-counter drugs, we will also discuss the potential effect of NSAID use 
on cancer treatment. Aspirin and other NSAIDs may have the capacity to perturb DNA 
repair pathways and this may have important implications for the patient response to 
chemotherapeutic agents. It is also worth noting that inflammation – the ‘seventh hallmark’ 
of cancer (Colotta et al., 2009) - can possibly repress (by epigenetic mechanisms) DNA 
mismatch repair.  
2. Cancer and NSAIDs 
From evidence adduced from epidemiological studies and clinical trials, it has been 
proposed that regular ingestion of aspirin and other non‐steroidal anti‐inflammatory 
drugs (NSAIDs) can promote colorectal tumour regression and reduce the relative risk of 
developing colorectal cancer (CRC) in the general population and in genetically 
susceptible individuals (for example see; (Baron et al., 2003; Chan et al., 2009; Cuzick et al., 
2009; Giovannucci, 1999; Imperiale, 2003; Logan et al., 1993; Paganini-Hill, 1993; Sandler et 
al., 2003; Thun et al., 2002). NSAID use is also associated with a reduced risk of 
oesophageal adenocarcinoma particularly in patients with high risk molecular 
abnormalities, for example, with 17p LOH, 9p LOH, and DNA content abnormalities 
(Galipeau et al., 2007). Recent meta-analyses of randomised clinical trials have 
strengthened the contention that aspirin has protective effects against CRC (Din et al., 
2010) and non-CRC related adenocarcinomas, including oesophageal and lung cancer 
(Rothwell et al., 2011). Although such studies have now provided substantial evidence 
that regular use of aspirin based medication can reduce the risk of colorectal cancer 
(Bosetti et al., 2002; Muscat et al., 1994; Thun et al., 1991) the molecular basis for the 
protective effect of aspirin vis-à-vis CRC and other cancers is rather controversial. A 
substantial number of theories are now in circulation. Whilst much of the focus in the 
recent past has understandably been on the intrinsic anti-inflammatory nature of the 
compounds in use, see for example, (Giovannucci, 1999; Keller & Giardiello, 2003), there 
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are a number of intriguing findings which suggest that NSAIDs can impact upon genetic 
stability and it is these aspects which we wish to highlight in this chapter. However, the 
optimism that arises from the findings that NSAIDs may offer protection against cancer 
should be tempered: NSAID use can result in serious side effects (gastrointestinal 
disturbances and cardiovascular events) in susceptible individuals (Cuzick et al., 2009). 
This has lead to considerable debate amongst clinicians over recent years as to whether 
NSAIDs should be prescribed as chemopreventative agents, in particular, to those 
individuals at high risk of developing colorectal cancer, such as HNPCC or Familial 
Adenomatous Polyposis (FAP) patients. 
Animal studies confirm that NSAIDs can protect against the development of colorectal 
neoplasia (Corpet & Pierre, 2003, 2005). For example, aspirin has been shown to suppress 
spontaneous intestinal adenoma formation and reduce incidence and volume of colon 
tumour induced by the carcinogen 1,2‐dimethylhydrazine in rat models (Barnes & Lee, 
1999). Continuous administration of a clinically relevant aspirin dosage was crucial in these 
studies in comparison to other studies where aspirin was administered at the start of 
carcinogenesis or one week after carcinogen exposure (Craven & DeRubertis, 1992). Taken 
together with findings from epidemiological studies in humans, there is thus the suggestion 
that long term, continuous usage of aspirin is required to gain any beneficial 
chemopreventative effects. Several studies carried out in the 1990s demonstrated inhibition 
of carcinogen induced tumour development by NSAIDs including aspirin and sulindac in 
rats (Rao et al., 1995; Reddy et al., 1993) and also in a murine model of FAP (Barnes & Lee, 
1998; Chiu et al., 1997; Jacoby et al., 1996; Mahmoud et al., 1998; Oshima et al., 1996). Familial 
adenomatous polyposis (FAP) is a colorectal cancer syndrome inherited in humans in an 
autosomal dominant manner caused by an absence of a functional caretaker APC protein 
(Narayan & Roy, 2003). Lifetime administration of aspirin to a mouse model with germline 
defects in both the APC and Msh2 gens (APC Min/+ , Msh2 -/-) suppresses intestinal and 
mammary neoplasia formation (Sansom et al., 2001).  
Epidemiological studies have identified environmental and dietary factors which alter the 
risk of developing colorectal cancer. Protective dietary factors include NSAIDs, fruit, 
vegetables, and folic acid and possibly calcium, whilst red and processed meat ingestion, 
alcohol use and obesity are perceived to increase risk (Forte et al., 2008; Key, 2011; La 
Vecchia et al., 2001; Ryan-Harshman & Aldoori, 2007; Scheier, 2001; Serrano et al., 2004). An 
assessment of chemopreventative measures, such as NSAID and micronutrient intake, for 
the general population and individuals with an increased risk for colorectal cancer based on 
family history, has recently been published (Cooper et al., 2010).  
2.1 Inflammation and cancer 
Debate has arisen with regards to the molecular mechanism of action of aspirin and other 
NSAIDs in reducing the incidence of certain cancers. Based on the anti-inflammatory effects 
of these agents, one obvious explanation is that inflammation can drive cancer development. 
Indeed, inflammation is becoming increasingly recognised as being critical to cancer 
formation, and building on the framework proposed by Hannahan and Weinberg (Hanahan 
& Weinberg, 2000), it has been proposed that inflammation should be considered the 
seventh hallmark of genetic instability (Colotta et al., 2009). It has been estimated that one in 
four cancers are linked to infection and chronic inflammation (Hussain & Harris, 2007). In 
an inflammatory microenvironment mutation frequency is increased (Bielas et al., 2006). 
There is strong evidence for an increased risk of cancer in individuals with chronic 
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inflammatory states (inflammatory bowel disease, gastroesophageal reflux disease, asthma) 
with or without attendant bacterial or viral infection (eg Helicobacter pylori, hepatitis) 
(Grivennikov & Karin, 2010; Schetter et al., 2010; Xie & Itzkowitz, 2008). The molecular 
drivers of cancer formation resulting from the interaction of pre-cancerous cells with 
activated immune cells and the surrounding stroma are complex. The host response to 
infection, injury and wound repair through production of reactive oxygen (ROS) and 
nitrogen oxide (RNOS) species, and pro-inflammatory cytokines (eg TNF-α, IL-1, IL-6) and 
chemokines (eg IL-8) (Wang et al., 2009) is of central importance. Such ‘micro-cytokine’ 
storms can stimulate activation of transcriptions factors (eg Nuclear Factor-κB, AP-1, 
STAT3) fundamentally altering the expression profile of a cell and promoting cell survival, 
proliferation, angiogenesis, motility and invasion. It is clear that for individual transcription 
factors their activation can be context (eg tissue) dependent and they may not always 
promote tumour cell formation, and may indeed exhibit tumour suppressor activity (eg NF-
κB in skin cancer) (Chaturvedi et al., 2011; Ditsworth & Zong, 2004). 
Microsatellite instability has been observed in non-neoplastic tissue in patients with chronic 
inflammatory conditions prior to the presence of dysplastic tissue, indicating that defects in 
DNA MMR can be an early event in inflammation-associated cancers (Brentnall et al., 1995; 
Park et al., 1998). There are tantalising findings which hint at the molecular basis for this 
MSI. Oxidative stress, in the guise of H2O2, increases frameshift mutations (Gasche et al., 
2001), and can inactivate the DNA MMR system (Chang et al., 2002). Moreover, in a p53 and 
p21 dependent fashion, activated neutrophils induced replication errors and a G2/M arrest 
in colonic epithelial cells (Campregher et al., 2008). In inflammatory bowel disease neoplasia, 
hypermethylation of the hMLH1 gene and reduced hMLH1 protein expression occurs 
frequently (Fleisher et al., 2000). In an animal model of colorectal cancer, inflammation and 
hypoxia were found to epigenetically silence hMLH1 expression: down-regulated 
expression of this DNA mismatch repair gene occurred as a consequence of decreased 
acetylation, which was reversible when the animals were treated with the HDAC inhibitor 
suberoylanilide hydroxamic acid (SAHA) (Edwards et al., 2009). Decreased expression of 
hMLH1 can alter hPMS2 stability and consequently, genetic integrity. Moreover, hMLH1 
and hPMS2 can have a role in activating cell-cycle checkpoints and promoting apoptosis 
(Cejka et al., 2003; Davis et al., 1998; Ding et al., 2009; McDaid et al., 2009; Sansom et al., 2003; 
Yanamadala & Ljungman, 2003; Zhang et al., 1999). Thus, a functional DNA mismatch repair 
system prohibits expansion of cells containing DNA damage (Carethers et al., 1996; Papouli 
et al., 2004). Dysregulated hMLH1/hPMS2 expression could conceivably impact on the 
survival of cells containing damaged DNA and promote cancer progression. hMLH1 
expression has been reported to be altered by tobacco usage and inflammatory state in the 
epithelium of the oral mucosa (Fernandes et al., 2007). Increased tissue specific hMLH1 
hypermethylation has been observed in the progression of oesophageal cancer (Vasavi et al., 
2006); the authors also reported that patients with gastroesophageal reflux disease (GERD) 
exhibited a very significant degree of hMLH1 hypermethylation prompting the suggestion 
that reflux can promote hypermethylation. The relationship between acid reflux and 
inflammation in GERD has been recently reviewed (Orlando, 2010). The phenomenon of 
elevated microsatellite instability at selected nucleotide repeats (EMAST) is also seen in 60% 
of sporadic colon cancers, is more common in individuals of African-American origin and 
has been linked to reduced expression of the hMSH3 protein. Moreover, EMAST is also 
more prevalent in rectal cancer with immune cell infiltration (Devaraj et al., 2010; Lee et al., 
2010). As MSI in CRC can result in products with potentially increased immunogenicity, it is 
www.intechopen.com
 
Non-Steroidal Anti-Inflammatory Drugs, DNA Repair and Cancer 747 
possible that this further stimulates inflammation (Banerjea et al., 2004). Tumour infiltrating 
lymphocytes in CRC with MSI are activated and cytotoxic (Phillips et al., 2004). In a model of 
experimental colon carcinogenesis in rats, long-term, low-dose administration of aspirin 
significantly reduced cytokine and matrix metalloproteinase release (Bousserouel et al., 
2010). Based on the above findings, it would appear to be reasonable to suppose that 
research into the epigenetic modifying effects of NSAIDs, and inflammation itself (Maekawa 
& Watanabe, 2007), particularly with respect to alterations in DNA repair protein expression 
and MSI, should be a focus in the future.   
Oxidative stress occurs as a consequence of the activation of the immune system, where 
oxidative bursts have a role in protecting the host against microbial invaders. Reactive 
oxide and nitrogen oxide species (ROS and RNOS) thus produced can ultimately cause 
DNA damage such as abasic sites, oxidised bases, DNA-intrastrand adducts, strand 
breaks, as well as RNA alkylation, and protein damage (Hussain et al., 2003). Reaction 
with lipids produces extremely reactive peroxidation products, including 
malondialdehyde (MDA) and trans-4-hydroxynonenal (4-HNE). 4-HNE can form etheno 
adducts in DNA and has been found to preferentially form adducts in codon 249 of the 
human p53 gene (Federico et al., 2007; Hu et al., 2002). Mutations in the tumour 
suppressor p53 are found in inflamed tissue in ulcerative colitis (UC) patients (Hussain et 
al., 2000). Accelerated telomere shortening, and DNA damage - as assessed by analysis of 
phosphorylated histone H2AX (γH2AX; a measure of DSBs) occurs in the bowel of UC 
patients (Risques et al., 2008). ROS and RNOS - whilst generally perceived as having a 
negative impact on cell function - do have important roles as secondary messengers 
(Valko et al., 2006). However, if the cellular defence mechanisms - anti-oxidant enzymes 
such as manganese superoxide dismutase and glutathione peroxidise, detoxification, and 
DNA repair systems - are overwhelmed, these reactive species are potentially mutagenic 
(Ferguson, 2010). The bystander effects from released cytokines and reactive signalling 
species may also occur some distance from the initial trauma. Redon et al. have shown 
that increased levels of DNA damage (measuring γH2AX levels) can occur systemically in 
mice implanted with a non-metastatic tumour (Redon et al., 2010). Animal model studies 
confirm the role of RNOS and the inflammatory process in contributing to cancer 
development (Hussain et al., 2003; Itzkowitz & Yio, 2004). 
The base excision repair (BER) system is critically important for dealing with oxidative 
damage to DNA, such as removal of 8-oxo-G lesions (David et al., 2007; Lindahl & Wood, 
1999; McCullough et al., 1999; Wood et al., 2001). Increased expression of the BER proteins 
AAG (a 3-methyladenine DNA glycosylase) and APE1 (apurinic endonuclease1; Ref-1) is 
seen in inflamed tissue from UC patients. Paradoxically a positive correlation of MSI was 
noted with overexpression of AAG, and for MSI-high tissues with increased APE1 
expression. In model systems this adaptive response was confirmed to positively correlate 
with an in increase in MSI in human cells and frameshift mutations in S. cerevisiae (Hofseth 
et al., 2003). Dysregulated expression of BER proteins can generate a mutator phenotype 
(Glassner et al., 1998) (as cited in Hofseth, 2003). In a mouse model of UC, expression of the 
Mutyh BER protein, which can recognise 8-oxoG:A mispairs and oxidised adenines was 
actually found to influence the inflammatory response to dextran sulphate sodium induced 
oxidative stress (Casorelli et al. 2010). The biomediator signalling molecule nitric oxide (NO.) 
formed during inflammation has the capacity to inhibit in vitro and in vivo the 
formamidopyrimidine-DNA glycosylase, which can recognise abasic sites and 8-oxoguanine 
lesions (Wink & Laval, 1994). Thus, oxidative stress can compromise genetic stability. 
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RNOS, and inflammatory cytokines and chemokines can activate the transcription factors 
activator protein-1 (AP-1), HIF-1 and NF-κB, the latter resulting in transcription of target 
genes including COX-2 and TNF-α (for example, see Olson & van der Vliet, 2011; Valko et 
al., 2006). DNA double strand breaks can also activate NF-κB (Rakoff-Nahoum, 2006), thus 
potentially creating a feedback loop where the inflammatory response is perpetuated. 
Persistent DNA damage can also trigger secretion of cytokines such as IL-6 (Rodier et al., 
2009). There is evidence that NF-κB and cyclooxygenase activation and HIF-1 signalling are 
interlinked (Jung et al., 2003; Qiao et al., 2010). Hypoxia can induce MSI (Kondo et al., 2001): 
in human sporadic colon cancers HIF-1α over-expression is associated with loss of hMSH2 
expression, and in vitro experiments confirm that in a p53 dependent manner HIF-1α can 
repress hMSH2 and hMSH6 (Koshiji et al., 2005; To et al., 2005). Recently HIF-1α has been 
suggested to regulate expression of an inhibitor of apoptosis protein, Survivin (Wu et al., 
2010), which is notably present in CRC (Chen et al., 2004). There is increasing evidence that 
microRNAs (short, non coding RNAs that regulate translation) are mediators of the 
inflammatory process (Schetter et al., 2010). Two micro-RNAs, miR-210 and miR-373 are up 
regulated in an HIF-1α dependent manner in hypoxic cells: forced expression of mir-210 
reduced expression of homologous recombination factor RAD52, whilst reduced mir-373 
expression was found to suppress RAD52 and RAD23B (Crosby et al., 2009). Over-
expression of another micro-RNA, miR-155 has been reported in colorectal cancer, and can 
regulate DNA MMR protein expression (Valeri et al., 2010). Inflammation can up-regulate 
miR-155 expression and increase mutation frequency two to threefold in spontaneous 
hypoxanthine phosphoribosyltransferase gene mutation assays (Tili et al., 2011). MiR-155 
expression is associated with a poor prognosis in lung cancer (Yanaihara et al., 2006). The 
cyclooxygenase family of enzymes (COX-1: constitutively expressed; COX-2: induced in 
inflammation; COX-3: splice variant of COX-1) catalyse the conversion of arachidonic acid 
into prostanoids (prostaglandins and thromboxanes). Cyclooxygenase expression is 
increased in CRC (Kutchera et al., 1996). Prostaglandins promote epidermal growth factor 
receptor (EGFR) transactivation, increased cell proliferation, motility, invasion and 
angiogenesis (eg by altering vascular endothelial growth factor expression) and inhibit 
apoptosis, for example, by increasing Bcl-2 expression (Ghosh et al., 2010; Pai et al., 2003; 
Sheng et al., 1998; Wang & DuBois, 2008). To summarise: inflammation and hypoxia can 
result in genetic instability and suppression of apoptosis. 
2.2 Mechanistic aspects of NSAID cytotoxicity  
The mechanism by which NSAIDs protect the host from colorectal cancer development has 
been under investigation for decades, and as a consequence a plethora of hypotheses (some 
of which may be competing) have been proposed to explain this phenomenon. In addition 
to the evidence alluded to above of epidemiological studies and animal models examining 
the protective effect of NSAIDs, there also exists a substantive literature reporting that 
NSAIDs exhibit a degree of specific toxicity in vitro to colorectal cancer cell lines. Because of 
the intrinsic anti-inflammatory activity of NSAIDs a significant number of researchers have 
focused on this aspect as a protective mechanism. For example, aspirin can acetylate the 
cyclo-oxygenases (COX) significantly reducing arachidonic acid metabolism and 
prostaglandin production, thereby reducing inflammation (Elwood et al., 2009). Expression 
of the inducible COX, cyclooxygenase-2 is notably elevated in colorectal malignancies and in 
other cancers (Ferrandez et al., 2003; Kutchera et al., 1996; Soslow et al., 2000), and this over-
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expression has been actively implicated in the metastasic potential of tumours (Jang et al., 
2009; Tsujii et al., 1997). These effects, however, may not be restricted only to colorectal 
cancer: a case control study has found that use of selective and non-selective COX-2 
inhibitors (celecoxib, refecoxib and aspirin and ibuprofen) has utility in the 
chemoprevention of lung cancer (Harris et al., 2007).   
NSAIDs do not only affect cyclooxygenase activity: exposure to these drug can significantly 
alter gene expression and thus NSAIDs can be reasonably described as having pleiotropic 
effects, some of which may be relatively compound dependent. Chronic NSAID use can 
suppress CpG island hypermethylation of tumour suppressor genes [p14(Arf), p16(INK4a), 
E-cadherin] in the human gastric mucosa (Tahara et al., 2009). Furthermore, NSAID toxicity 
may not be absolutely dependent on inhibition of COX activity: the proliferation of COX-2 
negative cell lines can also be inhibited by NSAIDs (Lai et al., 2008; Richter et al., 2001) and 
the chemical precursor of aspirin - salicylate - which has weak anti-COX activity, can itself 
be anti-inflammatory (Amann & Peskar, 2002) and pro-apoptotic to CRC cells (Elder et al., 
1996). Additionally, whilst the NSAID sulindac sulfide and its sulfone derivative can both 
inhibit the HT-29 CRC cell line growth, sulindac sulfone is “devoid of prostaglandin 
inhibitory activity” (Piazza et al., 1995). Additionally, aberrant crypt foci formation in a 
chemically induced rat model of CRC were suppressed by treatment with sulindac sulfone 
(Charalambous & O'Brien, 1996). Supporting these findings, a mechanism for NSAID 
toxicity (anti-proliferative and inducing apoptosis) – testing sulindac sulfide and piroxicam - 
toward a CRC line lacking cyclooxygenase activity (HCT-15) and thus independent of 
prostaglandin inhibition, has also been reported (Hanif et al., 1996). Sulindac metabolites 
(sulphide and sulfone; see Fig.1) can inhibit the activation and expression of the EGF 
receptor (Pangburn et al., 2005), with the down-regulated activity mediated by lysosomal 
and proteasomal degradation(Pangburn et al., 2010). Rigas and others have cogently 
proposed that the anti-neoplastic activities of NSAIDs can be categorised as either being 
COX-dependent or COX-independent (Keller & Giardiello, 2003; Shiff & Rigas, 1999). This 
concept has been reviewed in some detail in (Ferrandez et al., 2003). Smith et al examined the 
effects of NS-398 (a selective COX inhibitor), indomethacin (a non-selective COX inhibitor) 
and aspirin on the HT29Fu, HCA-7, SW480 and HCT116 CRC cell lines with respect to 
effects on cell proliferation, cell cycle arrest, apoptosis induction, β-catenin and COX-1 and 
COX-2 protein production. They concluded that NSAIDs act via COX-dependent and COX-
independent mechanisms (Smith et al., 2000). Indeed, acetylsalicylic acid regulates MMP-2 
activity and inhibits colorectal invasion of B16F0 melanoma cells (Tsai et al., 2009). 
Intriguingly, although medium conditioned by cultured colorectal cancer cell lines is 
capable of inducing endothelial cell (EC) tube formation (as a model for angiogenesis); 
aspirin and salicylate (both at 1mM) can reduce the ability of the conditioned medium from 
treated DLD-1, HT-29 and HCT116 CRC cell lines to promote EC tube formation 
(Shtivelband et al., 2003). 
Aspirin is principally metabolised to salicylate in vivo (Law et al., 2000; Paterson & 
Lawrence, 2001), with plasma salicylate concentrations of 0.95-1.9 mM achievable in patients 
receiving aspirin as an anti-inflammatory agent (Amann & Peskar, 2002; Urios et al., 2007; 
Yin et al., 1998). The effect of significantly higher concentrations than that achievable 
physiologically has been used by a number of investigators in a number of in vitro studies 
and one must interpret cautiously data produced from these analyses. To facilitate 
interpretation, we have incorporated the concentrations utilised in the relevant publications. 
We should also point out that whilst vegetables and fruits have been considered to be a 
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natural source of salicylate, where it functions as a plant signalling molecule (Paterson & 
Lawrence, 2001; Schenk et al., 2000, and refs therein), it has been reported that SA may be an 
endogenous compound, with SA found in the blood of carnivorous animals, for example in 
the burrowing owl (Paterson et al., 1998; Paterson et al 2008). 
 
 
Fig. 1. The non-steroidal anti-inflammatory drugs (NSAIDS) referred to in this chapter can 
be sub-categorised into five groups. 1. Salicylates (salicylic acid/salicylate anion, aspirin, 5-
aminosalicylic acid). 2 Acetic acid derivatives (indomethacin, sulindac sulphide, sulindac 
sulphone) 3. Propionic acid derivatives (ibuprofen). 4. Enolic acid derivatives or oxicams 
(piroxicam). 5. Selective COX-2 inhibitors (celecoxib, rofecoxib, NS-398). Curcumin has a 
dimeric structure with two identical phenolic moieties suggestive of salicylate-like character. 
2.2.1 COX independent effects of NSAIDs  
A substantial number of hypotheses regarding NSAID cytotoxicity not directly involving 
inhibition of COX activity exist (reviewed in: Goke, 2002; Watson, 2006). Much of the data is 
obtained from examining the effect of NSAIDs on cultured cell lines. For example, salicylate 
can cause cell cycle arrest: in a range of adenoma and carcinoma derived cell lines, 
incubation with 5 mM resulted in a decrease of cells in the S-phase with cells accumulating 
in the Go-G1 phase (Elder et al., 1996). Activating mutations stabilizing the Wnt pathway and 
β-catenin are common in CRC (Behrens, 2005; Bienz & Clevers, 2000). In four CRC cell lines 
(SW948, SW480, HCT116, LoVo), aspirin (5 mM) and indomethacin (400 µM) downregulated 
cyclin D1 expression, and the authors proposed this was a consequence of reduced 
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transcriptional activity of the β-catenin/TCF complex (Dihlmann et al., 2001). Bos et al using 
reporter assays also showed that aspirin (up to 5 mM) can down-regulate APC-β-catenin-
TCF4 signalling in the SW480 CRC cell line and increase the phosphorylation of protein 
phosphatase 2A (PP2A), resulting in decreased PP2A enzymatic activity. This alteration is 
stated to be essential for the observed effect on the Wnt/β-catenin pathway activity (Bos et 
al., 2006). Mutations in the APC or β-catenin genes may also result in increased peroxisome 
proliferator-activated receptor δ (PPAR δ) activity; indeed, sulindac sulfide and 
indomethacin have been reported to suppress (by direct inhibition) in a dose-dependent 
fashion, PPARδ activity (He et al., 1999). However, it should be noted that regulation of 
PPARδ by the APC/ β -catenin/TCF4 pathway and the effect of NSAIDs on PPAR function 
is a field not without some controversy; for example, Foreman et al recently reported not 
finding decreased PPARβ/δ expression following NSAID treatment in a number of human 
CRC cell lines (Foreman et al., 2009).  
2.2.2 NSAIDS, signalling pathways and apoptosis 
Other transcriptional pathways affected by NSAID use include NF-κB signalling, which is 
critically involved in regulating immunity, inflammation and apoptosis and in cancer 
development (Nakano, 2004; Olivier et al., 2006; Staudt, 2010). Aspirin and sodium salicylate 
can antagonise the NF-κB pathway (Kopp & Ghosh, 1994), via inhibition – by direct, but not 
covalent binding- of IκB kinase-B (IKK β kinase) (Yin et al., 1998). Yamamoto et al extended 
this hypothesis by reporting that sulindac, sulindac sulfide and sulindac sulfone (but not 
indomethacin) also inhibits the NF-κB pathway by decreasing IKK β kinase activity 
(Yamamoto et al., 1999). In HT-29 CRC cells, nitric oxide (NO)-donating aspirin inhibited 
NF-κB transcription more potently than aspirin as assessed by electrophoretic mobility shift 
assays (Williams et al., 2003). 
Zerbini et al reported that NF-κB can mediate the repression (assessed by RT-PCR analysis) 
of the growth arrest and DNA damage inducible (GADD) 45α and GADD45γ genes and that 
this repression is both necessary and sufficient for cell survival, and that GADD45α and γ 
activity can contribute towards apoptosis of prostate cancer cells (assessed by transfection 
studies in DU145 and PC-3) (Zerbini et al., 2004).  The melanoma differentiation associated 
gene 8 (mda-7/IL-24) was induced by NSAIDs and affected growth arrest and apoptosis in  
 
vitro, in a manner dependent on GADD45α and γ expression affecting the p38/JNK pathway 
(Sarkar et al., 2002; Zerbini et al., 2006). However, it has been suggested that recombinant IL-
24 lacks apoptosis inducing properties to melanoma cells (Kreis et al., 2007). In a recent 
review, Siafakas and Richardson have suggested that the GADD family of proteins can be 
considered to be molecular targets for anti-tumour agents; indeed, commonly used NSAIDs 
can up-regulate GADD45α expression (Rosemary Siafakas & Richardson, 2009). 
GADD45α overexpression in NIH 3T3 cells has been shown to promote global  
DNA demethylation and loss of expression has been shown to induce DNA 
hypermethylation (including in hMLH1). Such findings led Barreto et al to conclude that 
GADD45α can relieve epigenetic silencing by promoting DNA repair (Barreto et al., 2007). It 
is noteworthy that GADD45γ can be inactivated by epigenetic mechanisms in multiple 
tumours (Ying et al., 2005).  
In a review of the role of the NF-κB pathway in inflammation and cancer, the authors 
suggested that, ’...constitutive NF-κB activation is likely involved in the enhanced growth 
properties seen in a variety of cancers’ (Yamamoto & Gaynor, 2001). Specifically targeting 
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the NF-κB pathway may thus have utility in cancer treatment (Olivier et al., 2006): for 
example, attempts are ongoing to identify clinically useful and novel IKK-β inhibtors (for 
example see (Lauria et al., 2010)), and inhibition of NF-κB (by siRNA) can enhance the 
chemosensitivity of HCT116 CRC cells to the DNA topoisomerase inhibitor, irinotecan (Guo 
et al., 2004). In marked contrast however, Stark et al, have suggested that aspirin can activate 
NF-κB signalling in vitro (SW480, HRT-18, HCT116, CT26 cell lines) and has the capacity to 
induce apoptosis in in vivo (xenografts and APC Min+/-) models of CRC (Stark et al., 2001; 
Stark et al., 2007). Moreover, these effects are cell type specific to aspirin (for CRC cells): the 
induction of apoptosis was independent of COX-2 expression, APC and β-catenin mutation 
status, and DNA mismatch repair proficiency (Din et al., 2004).  
A number of other hypotheses have been invoked for the observed cytotoxicity of NSAIDs 
to CRC cell lines. Cytosolic phospholipase A2 (cPLA2) expression is decreased in NIH 3T3 
cells treated with either aspirin or sulindac (Yuan et al., 2000) and in CRC cell lines (SW480, 
Colo320 and HT-29) when treated with low mM (2.5-10) concentrations of aspirin (Yu et al., 
2003). This observation is intriguing given that cPLA2 expression has been proposed to 
participate in intestinal tumorigenesis (eg (Lim et al., 2010) and refs therein). Law et al have 
indicated that (high mM concentrations of) salicylate (in Balb/MK cells) can inhibit the 
activity and phosphorylation of the mitogen activated protein kinase, p70s6k independent of 
p38 MAPK, with a concomitant reduction in DNA synthesis, cell proliferation and in 
expression of proliferation associated proteins such as c-MYC, cyclin D1, and PCNA and led 
the authors to conclude that salicylate may act via the mTOR pathway (Law et al., 2000). In 
contrast, it has been suggested that salicylate-induced apoptosis in HCT116 CRC cells occurs 
through activation of p38 MAPK and p53; however, the concentration tested was - in our 
opinion - high (10mM), and thus casts doubt on the utility of the findings (Lee et al., 2003). 
NO-donating aspirin has also been reported to activate p38 and JNK MAP kinase pathways 
in HT-29 colorectal cancer cells (Hundley & Rigas, 2006). Using subtractive hybridization, 
Baek et al identified an increase in the expression of the NSAID activated gene (NAG-1) – a 
member of the TGF-β superfamily, with pro-apoptotic properties - in indomethacin treated 
HCT116 cells. A range of NSAIDs including sulindac sulfide and aspirin also increased 
NAG-1 expression (Baek et al., 2001). NCX-4040 (para-NO-aspirin), an NO donating aspirin 
derivative can also induce NAG-1 expression and it was confirmed that NAG-1 has a pro-
apoptotic role (Tesei et al., 2008, and refs therein). Another nitro-derivative of aspirin, NCX-
4016 inhibited EGFR and STAT3 signalling in cisplatin-resistant human ovarian cancer cells 
(Selvendiran et al., 2008). NSAIDs can also up-regulate 15-lipoxygenase-1 (15-LOX-1) in CRC 
cells: NS-398 and sulindac sulfone both induced expression in the DLD-1 (COX-1 and COX-2 
negative) cell line; significantly, inhibiting 15-LOX-1 blocked the induction of apoptosis 
(Shureiqi et al., 2000).  
With respect to characterisation of the pathway by which NSAID toxicity occurs, reports 
have been rather contradictory: in vitro studies have suggested that whilst aspirin and other 
NSAIDs can cause cell cycle arrest and inhibit CRC proliferation, this may, (Din et al., 2004; 
Elder et al., 1996; Piazza et al., 1995; Yu et al., 2002; Yu et al., 2003) or may not (Shiff et al., 
1996; Smith et al., 2000) occur with the induction of apoptosis, or may occur as consequence 
a combination of activation of both apoptotic and necrotic ‘pathways’ (Lai et al., 2008).  
Notwithstanding the apparently contradictory reports, an absence of Bax expression in CRC 
cells has been found to abolish the apoptotic response to NSAIDs (Zhang et al., 2000). These 
authors reported finding Bax mutations in indomethacin resistant cells. Bax and BCl-2 
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expression can be up and down-regulated respectively, in a dose-dependent fashion, (up to 
10 mM) in SW480 cells incubated with aspirin (Lai et al., 2008). BCL-2 expression can be 
reduced by aspirin in SW480 cells (Yu et al., 2002) and can also suppress apoptosis in CRC 
cells (Jiang & Milner, 2003). Pretreating LNCap (human prostate) and CX-01 (colorectal 
carcinoma) cell lines with aspirin was found to enhance the capacity of tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) to intiate apoptosis, an effect – according 
to the authors - related to down regulation of BCL-2 gene expression resulting from the 
inhibition of NF-κB (of which BCL-2 is a known target) (K.M.Kim et al., 2005). HeLa cells 
incubated with aspirin undergo apoptosis as assessed by cleavage of procaspase 3, PARP 
and PKC-δ, and annexin V staining. Moreover, the caspase inhibitor zVAD-fmk suppressed 
cell death, Bax was noted to translocate from the cytosol to mitochondria, and cytochrome c 
release from mitochondria was seen using time-lapse confocal microscopy (Zimmermann et 
al., 2000). Sulindac sulfide (up to 500 µM tested) can inhibit growth of NIH3T3 and SAOS 
cells: an inhibtion of ras mediated proliferation and transformation was noted (Herrmann et 
al., 1998). Hughes et al., (2003) showed that NSAID treatment of colorectal cancer cell lines 
caused a decrease in intracellular polyamine content and was cytotoxic. Polyamines are 
growth factors, and involved in protein synthesis. An increase in intracellular polyamine 
concentration is observed in the early stages of carcinogenesis. When polyamines were re-
introduced to NSAID treated cells, apoptosis was inhibited suggesting that the polyamine 
pathway is affected by NSAID treatment in CRC cell, and that modulation of this pathway 
may explain the chemoprotective effects of NSAIDs (Hughes et al., 2003). Dikshit et al., 
reported that aspirin disrupted proteasome and mitochondrial function in mouse Neuro 2a 
cells (Dikshit et al., 2006). Hardwick et al., (2004) analysed changes to gene expression 
employing DNA microarray in the colorectal cancer cell line HT-29 upon aspirin treatment, 
and found a significant increase in Rac1 gene and protein expression in a time and 
concentration dependant manner. Rac1 is involved in intestinal epithelial cell differentiation 
(Stappenbeck & Gordon, 2000) proliferation, motility and resistance to apoptosis (Parri & 
Chiarugi, 2010). Spitz et al report that aspirin and salicylate can inhibit purified 
phosphofructokinase (PFK) in a dose-dependent manner: as cancer cells utilise glycolysis for 
energy production in which PFK is the rate limiting step, the authors suggest that these 
NSAIDs may be pro-apoptotic through disturbing the glycolytic pathway (Spitz et al., 2009). 
We have recently identified novel derivatives of di-aspirin (bis-carboxyphenol succinate) to 
have potential as anti-colorectal cancer agents (Deb et al., 2011). 
2.3 NSAIDS and DNA repair 
A relatively unexplored area of research is that the anti-tumour mechanism of action of 
aspirin may be via ‘interaction’ with the DNA repair systems. This is of key interest 
particularly in the context of hereditary and sporadic colorectal cancer where DNA repair 
defects can be a causative factor. It has been shown that the MSI mutator phenotype is 
suppressed by aspirin. For example, treatment of the colorectal cancer cell line HCT116 - 
which is DNA MMR deficient with a defect in hMLH1 - reduced the MSI phenotype and 
induced apoptosis (Ruschoff et al., 1998). It is speculated that aspirin exposure resulted in 
genetic selection against cells with MSI and that MSI unstable cells were weeded out by 
apoptosis (Ruschoff et al., 1998). This observation is important as MSI resulting from a 
genetic mutation in hMLH1, accounts for 5 - 10% of colonic tumours. Nitric oxide releasing 
NSAIDS (NO-NSAIDS) suppressed MSI in DNA mismatch repair deficient colorectal cancer 
cells (McIlhatton et al., 2007), and the authors suggested that since these NO containing 
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derivatives of aspirin are more effective than aspirin itself, they should be considered for use 
in chemopreventitive trials in patients at high risk of developing CRC. Recently, in a mouse 
model of HNPCC, McIlhatton et al., reported that aspirin and low dose NO-aspirin 
increased life span. However, though the intestinal tumours in aspirin treated animals 
showed less microsatellite instability, low dose NO-aspirin had ‘minimal effect on MSI 
status’ and high dose NO-aspirin decreased life span and increased MSI (McIlhatton et al., 
2011). In addition to the phenomenon of aspirin selecting for microsatellite stability in 
colorectal cancer cells (Ruschoff et al., 1998), aspirin in vitro can inhibit CRC growth and 
increase the level of the DNA MMR proteins hMLH1, hMSH2, hMSH6 and hPMS2 in DNA 
MMR proficient cells (Goel et al., 2003). Increased DNA MMR levels could conceivably 
facilitate programmed cell death. This is a highly significant observation as defects in 
DNA MMR proteins are ultimately responsible for HNPCC and this study speculates in 
particular on the involvement of MLH1 function in the chemoprotective effect of aspirin. 
In addition to this, recent evidence has shown that although MLH1 expression is 
decreased in cases of sporadic colorectal adenoma, MLH1 expression was found to be 
increased in cases of sporadic colorectal adenomas with regular aspirin use (Sidelnikov et 
al., 2009). Aspirin is not alone in having the capacity to select for microsatellite stability: 
the NSAID mesalazine (5-aminosalicylic acid), used to treat patients with inflammatory 
bowel disease (IBD), experimentally reduced frameshift mutations in cultured CRC cells 
(HCT116 and HCT116+chr 3) independent of DNA mismatch repair proficiency (Gasche 
et al., 2005). In vitro, mesalazine inhibits the growth of HCT116 and HT-29 cells, a result 
reported a consequence of the compound inhibiting CDC25A, a cell cycle protein (Stolfi et 
al., 2008). Studies have also implicated cell-cycle arrest as a cellular response to aspirin 
exposure (Lai et al., 2008; Ricchi et al., 1997). Decreased transcription of CCNB1 (Cyclin B1) 
which regulates cell-cycle progression at the G2/M phase by sulindac treatment has been 
observed (Iizaka et al., 2002). To summarise: NSAIDs can select for microsatellite stability 
and cause cell-cycle arrest. 
2.3.1 NSAIDs and DNA repair protein expression 
Microarray analysis has been extensively utilised to examine alterations in gene expression 
in response to NSAID exposure in a number of colon cancer cell lines (Germann et al., 2003; 
Hardwick et al., 2004; Huang et al., 2006; Iizaka et al., 2002; Yin et al., 2006). Hardwick et al., 
(2004) reported that cell-cycle related genes and NF-κB were repressed upon aspirin 
treatment. Iizaka et al., (2002) reported an increase in GADD45α upon treatment with the 
NSAID sulindac. However, although, microarray analysis has been previously carried out to 
determine the effects of aspirin on colorectal cancer (Hardwick et al., 2004; Iizaka et al., 2002) 
these studies have not looked specifically at DNA damage signalling pathways. In addition, 
Hardwick et al., (2004) and also Yin et al., (2006) have shown that notably different gene 
expression patterns are seen when different concentrations of NSAID are used. Both studies 
showed that at low concentrations (1 mM) aspirin elicited activation of a different set of 
genes in the colorectal cancer cell line HT‐29, compared to cells incubated with 5 mM 
aspirin. There is a lack of consistency in the literature regarding dosages utilised for both 
clinical and experimental studies. Intriguingly, clinical trials have shown that low dose 
aspirin (81mg) is more protective against colorectal cancer than ‘high’ dose aspirin (325mg) 
(Baron et al., 2003). The variation in experimental design, especially with regards to what 
dose is clinically relevant makes it problematic when deciding on appropriate drug 
concentrations for experimental work.  
www.intechopen.com
 
Non-Steroidal Anti-Inflammatory Drugs, DNA Repair and Cancer 755 
In addition to the report by Iizaka et al., (2002), a number of other studies have also shown 
NSAID regulation of growth arrest and DNA damage (GADD) gene expression. Germann et 
al (2003) analysed gene expression of CC531 colorectal cancer cells treated with 4.5mM 
Butyrate or 3mM aspirin and showed that GADD153 is up-regulated upon aspirin 
treatment. GADD153 expression has also been shown to be induced by celecoxib treatment 
in cervical cancer cells (Kim et al., 2007). Microarray analysis of the colorectal cancer cell line 
HT-29 treated with 1mM and 5mM aspirin showed an up-regulation of GADD45α (Yin et al., 
2006). Further to this, microarray analysis also shows GADD45 gene expression to be up-
regulated by NS-398 (Huang et al., 2006) and celecoxib (Fatima et al., 2008) in colorectal 
cancer cells and by ibuprofen in human gastric adenocarcinoma cell line (Bonelli et al., 2010). 
Suppression of GADD45α expression confers resistance to sulindac and indomethacin 
induced gastric mucosal injury and apoptosis (Chiou et al., 2010) . 
Other genes involved in DNA repair have also been shown to be regulated by NSAIDs. 
High concentrations of NS-398, ibuprofen, and RNAi mediated inhibition of COX-2  
in human prostate carcinoma cells affected genes involved in DNA replication, 
recombination and repair (John-Aryankalayil et al., 2009). PCNA gene expression has been 
shown to be up-regulated by ibuprofen treatment of a human gastric adenocarcinoma cell 
line (Bonelli et al., 2010), and also in the human hepatocellular carcinoma cell line HepG2 
treated with 25mM vanillin (Cheng et al., 2007). In contrast, down-regulation of PCNA gene 
expression has been reported in colorectal cancer cell lines treated with celecoxib suggesting 
that these compounds may modulate cell cycle regulation in these model (Fatima  
et al., 2008). Interestingly, FADD gene expression is down-regulated by NS-398 but up-
regulated by indomethacin in the colorectal cancer cell line Caco-2 (Huang et al., 2006). 
Sulindac has been reported to down-regulate XRCC5, ERCC5 and UNG gene expression in 
colorectal cancer cell lines (Iizaka et al., 2002). Celecoxib up-regulated ATM, MAP3K2, 
CDKN1A and Bax gene expression in the colorectal cancer cell line HCA-7; in contrast, Bax 
gene expression was down-regulated in the HCT116 cell line upon celecoxib treatment 
(Fatima et al., 2008) suggesting that there may be variation in response from cell line to cell 
line to NSAID exposure.  
We have recently reported finding that XRCC3 protein expression in SW480 cells was 
increased upon 1 mM aspirin treatment for 48 hours (Dibra et al., 2010). The altered 
expression of XRCC3 upon aspirin exposure may have implications to the sensitivity of cells 
to chemotherapeutic agents. Indeed, previous research in the breast cancer cell line MCF7 
demonstrated that over‐expression of XRCC3 induced cisplatin resistance (Xu et al., 2005). 
Studies have shown that in contrast to XRCC3 over‐expression and cisplatin resistance, 
XRCC3 deficient HCT116 cells have increased sensitivity to cisplatin and also mitomycin C 
(Yoshihara et al., 2004). Depletion of XRCC3 by siRNA in MCF7 cells inhibited cell 
proliferation, leading to accumulation of DNA breaks and triggering activation of p53‐
dependant cell death (Loignon et al., 2007). Although some studies have shown no 
association between polymorphisms in XRCC3 and colorectal cancer risk (Mort et al., 2003; 
Yeh et al., 2005; Tranah et al., 2004; Skjelbred et al., 2006) some studies have (Improta et al., 
2008), and in XRCC3 polymorphisms have also been associated with breast and lung cancer 
susceptibility (Smith et al., 2003; Jacobsen et al., 2004). One essential point to note is that there 
is a lack of information in current literature about the effects of NSAIDs on normal human 
colonocytes. The information that we have relates to cell lines/in vitro studies and murine 
models. There is a need to understand the effects of these compounds on normal, healthy 
colon cells and how these effects prevent carcinogenesis in these cells. With the majority of the 
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models used in studies already established as cancerous, it is difficult to separate the effects of 
these compounds on normal cells rather than cells which are already cancerous and subject to 
pathway dysregulation. In addition to NSAIDs, flavonoids have also been associated with 
anti—carcinogenic properties. It is interesting to note that a recent study has shown that these 
compounds, which occur naturally in fruits and vegetables, not only have a protective effect 
against oxidative DNA damage but also increase repair activity in vitro (Ramos et al., 2010). To 
summarise: NSAIDs can alter the expression of DNA repair, and pro- and anti-apoptotic 
proteins. 
2.3.2 Curcumin and DNA repair 
Curcumin is a naturally occurring turmeric derivative with anti-inflammatory properties 
and apoptotic, anti-proliferative, anti-oxidant and anti-angiogenic effects (Shehzad et al., 
2010). In vivo studies have shown that curcumin decreased intestinal polyp formation in the 
APCmin/+ mouse model (Murphy et al., 2010). Curcumin is considered an attractive 
compound for chemopreventative use and there are at present clinical trials ongoing testing 
the effectiveness of the compound against different types of cancer (Shehzad et al., 2010). 
However, as with aspirin, a known mechanism of action of curcumin is yet to be elucidated 
with a range of molecular targets proposed (as reviewed in Shehzad et al., 2010 and 
Ravindran et al., 2009). As discussed in a recent review (Burgos-Moron et al., 2010), although 
curcumin is widely regarded as a potential chemopreventative drug its safety and efficiency 
is yet to be fully elucidated and results from studies, clinical or otherwise, should be 
interpreted with this in mind. Curcumin has been shown to affect DNA damage and repair. 
Curcumin has been found to induce DNA damage in mouse-rat hybrid retina ganglion cells 
(Lu et al., 2009). The study reported that curcumin decreased expression of the DNA repair 
genes ATR, ATM, BRCA1, DNA-PK and MGMT. Curcumin has also been seen to cause DNA 
damage, as tested in the Comet Assay, in gastric mucosa cells and human peripheral blood 
lymphocytes (Blasiak et al., 1999). Curcumin has been shown to induce DNA single strand 
breaks (Scott & Loo, 2004) and induce the expression of the pro-apoptotic gene GADD153 in 
HCT116 colonocytes. It is suggested that the up-regulation of GADD153 is a direct response 
to DNA damage caused by curcumin, ultimately resulting in the induction of apoptosis 
(Scott & Loo, 2004). Microarray analysis of human lung cancer cells after curcumin 
treatment saw an upregulation of GADD45 and GADD153 gene expression (Saha et al., 
2010) and microarray analysis has also shown an up-regulation of GADD45 by curcumin 
treatment in a human breast cancer cell line (Ramachandran et al., 2005). It  
has recently been proposed that DNA MMR may play a role in the cellular response to 
curcumin (Jiang et al., 2010): DNA MMR proficient cells showed a greater accumulation  
of double strand breaks (DSB) upon curcumin treatment compared to MMR deficient cells 
suggesting that DSB formation induced by curcumin is primarily a DNA MMR-dependent 
process; further to this, curcumin was reported to activate ATM/Chk1 and cause cell-cycle 
arrest and apoptosis in human pancreatic cancer cells. DNA MMR proficient cells showed 
activation of Chk1 and induction of the G(2)-M cell cycle checkpoint (Jiang et al.,  
2010) suggesting that the curcumin induced checkpoint response may be a DNA MMR 
dependent mechanism. Interestingly, microarray analysis of gene expression of invasive 
lung adenocarcinoma (CL1-5) cells exposed to curcumin found an induction in MLH1 
gene expression and reduction in MMP expression (Chen et al., 2004). Curcumin is  
also reported to affect the Fanconi anemia (FA)/BRCA pathway. Curcumin sensitises 
ovarian and breast cancer cells with a functional FA/BRCA pathway to cisplatin 
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(Chirnomas et al., 2006). This is a clinically significant finding as resistance to 
chemotherapeutic drugs such as cisplatin is common and monoketone analogs of 
curcumin are now being developed as a new class of FA pathway inhibitors (Landais et 
al., 2009). Recently, curcumin inhibition of the FA/BRCA pathway has also been 
suggested to be a mechanism for the reversal of multiple resistance in a multiple myeloma 
cell line (Xiao et al., 2010). In a recent phase IIa clinical trial report, curcumin reduced 
aberrant crypt foci formation (Carroll et al., 2011). 
2.3.3 Interaction of NSAIDs with anti-cancer treatments 
The capacity for specific cyclooxygenase inhibitors and NSAIDs to enhance the cellular 
response to chemotherapeutic and radiotherapeutic agents has been examined. Additive, 
synergistic and antagonistic effects have been reported. For example, the effect of a selective 
COX-2 inhibitor SC-236 (4-[5-(4-chlorophenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl) benzene 
sulphonamide) was tested on cells derived from a murine sarcoma in the absence and 
presence of γ-ray irradiation, and a clonogenic cell survival assay confirmed that the 
compound significantly enhanced cell radiosensitivity (Raju et al., 2002). In the human 
hepatocellular carcinoma cell line HepG2, indomethacin and SC-236 enhanced doxorubicin 
toxicity reportedly via inhibiting P-glycoprotein and the multidrug resistance-associated 
protein 1 (MRP1) (Ye et al., 2011). Exogenous prostaglandin E2 addition failed to reverse the 
cellular accumulation and retention of doxorubicin and the authors concluded that the 
action of the drugs was via a COX-independent mechanism. Synergistic cell death 
characterised as being apoptotic based on Bax expression, DNA fragmentation and TUNEL 
assay, was observed in HT-29 cells co-treated with aspirin and 5-fluorouracil (Ashktorab et 
al., 2005). In marked contrast to the above findings, an antagonistic activity of celecoxib and 
SC-236 to cytotoxicity mediated by cisplatin to human esophageal squamous cell carcinoma 
cells has been observed; mechanistic analysis indicated that the compounds decrease 
cisplatin accumulation and DNA platination, in a COX-2 independent manner (Yu et al., 
2011). As previously intimated, there is evidence that NSAIDs can affect double strand 
break repair pathways. It is known that the homologous recominbation protein Rad51 is 
overexpressed in chemo-radioresistent carcinomas. A study by Ko et al., (2009) showed that 
celecoxib enhanced gefitinib induced cytotoxicity in NSCLC cells: combined 
celecoxib/gefitinib treatment resulted in the reduction of Rad51 protein levels. Degradation 
of Rad51 occurred via a 26S proteasome-dependent pathway. Celecoxib has been shown to 
inhibit growth of head and neck carcinoma cells and enhance radiosensitivity in a dose-
dependent manner: celecoxib downregulated Ku70 protein expression and inhibited DNA-
PKcs kinase activity which is known to be involved in DSB repair (Raju et al., 2005). Further 
to this, sodium salicylate has been shown to inhibit the kinase activity of ATM and DNA-PK 
which suppresses their DNA damage response (Fan et al., 2010). A recent study in prostate 
cancer demonstrated that treatment of the prostate cancer cell line PC-3 with NO-sulindac 
increased the rate of single strand DNA breaks and that there was slower repair of these 
lesions (Stewart et al., 2011). We thus suggest that caution is exercised in situations where 
patients are prescribed NSAIDs when undergoing chemotherapy or radiotherapy as 
unexpected additive or antagonistic reactions may arise, and thus potentially compromise 
treatment effectiveness. However, there is also the promise that NSAIDs (either known or 
novel) may significantly synergise and enhance responses to chemotherapeutic, biologic, or 
radiotherapeutic modalities. 
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Fig. 2. A schematic illustration (composite) of the possible interconnections of the molecules 
and activities cited in the text. Where NSAIDs can potentially act is illustrated with X. 
Abbreviations: BER, base excision repair; CIN, chromosomal instability; COX, 
cyclooxygenase; DDR, DNA damage response; EGF, epidermal growth factor; Fpg, 
formamidopyrimidine-DNA glycosylase; 4-HNE, trans-4-hydroxynonenal; HIF-1α, hypoxia 
inducible factor-1α; MDA, malondialdehyde; MIN, microsatellite instability; MMP, matrix 
metalloproteinase; miR, micro RNA; NF-κB, nuclear factor kappa B; RNOS, reactive 
nitrogen oxide species; ROS, reactive oxygen species; STAT3, signal transducer and activator 
of transcription 3; VEGF, vascular endothelial growth factor. For reasons of clarity, 
chemokine and cytokine receptor interactions are not shown. 
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3. Conclusion 
The accumulated findings from a significant body of research indicates that NSAIDs –
including aspirin- act via multiple mechanisms in reducing the morbidity and mortality of 
cancer, and that aspirin and other NSAIDs reduce inflammation via COX-dependent and 
COX-independent pathways. NSAIDs can select for DNA mismatch repair competency and 
microsatellite stable cells thus inhibiting at least one well recognised pathway of colorectal 
cancer progression; furthermore, in vitro data suggest that NSAIDs exhibit ‘direct’ and 
relatively specific and rapid toxicity to colorectal cancer cells, with evidence suggesting that 
this may (but almost certainly not exclusively) involve DNA repair pathways. There is a 
paucity of information regarding the effect of NSAIDS on gene expression in non-
transformed cell lines, including colonocytes and stromal cells and stem cells. 
Epidemiological evidence strongly indicates that NSAIDs are particularly protective against 
adenocarcinoma formation. Given the potential as chemopreventative agents, significant 
effort should be directed into producing novel NSAID derivatives that do not produce the 
adverse gastrointestinal and cardiovascular effects but retain the multiple and potent 
protective actions that are involved in suppressing adenocarcinoma formation.  
We feel that the following questions need to be addressed: 
a. What is the mechanism by which aspirin selects for microsatellite stability? 
b. What is the mechanism by which aspirin and other NSAIDs show their relatively 
specific toxicity to colorectal cancer cells? 
c. Does long term usage of aspirin and other NSAIDs preferentially reprogram the colonic 
epithelium via epigenetic mechanisms eg altering histone deacetylase and DNA 
methyltransferase activities?  
d. How do NSAIDS affect gene expression in non-transformed cells, including colonic 
stem cells? Do NSAIDs affect epithelial miRNA profiles? 
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